Edgewise Non Operating Income Net Other from 2010 to 2024

EWTX Stock  USD 32.20  0.12  0.37%   
Edgewise Therapeutics Non Operating Income Net Other yearly trend continues to be fairly stable with very little volatility. Non Operating Income Net Other will likely drop to about 2.4 M in 2024. During the period from 2010 to 2024, Edgewise Therapeutics Non Operating Income Net Other regression line of annual values had r-squared of  0.42 and arithmetic mean of  1,059,580. View All Fundamentals
 
Non Operating Income Net Other  
First Reported
2010-12-31
Previous Quarter
4.6 M
Current Value
2.4 M
Quarterly Volatility
1.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 14.9 M, Interest Income of 14.9 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.3. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Edgewise Therapeutics Correlation against competitors.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Latest Edgewise Therapeutics' Non Operating Income Net Other Growth Pattern

Below is the plot of the Non Operating Income Net Other of Edgewise Therapeutics over the last few years. It is Edgewise Therapeutics' Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edgewise Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Non Operating Income Net Other10 Years Trend
Slightly volatile
   Non Operating Income Net Other   
       Timeline  

Edgewise Non Operating Income Net Other Regression Statistics

Arithmetic Mean1,059,580
Geometric Mean621,843
Coefficient Of Variation134.66
Mean Deviation1,052,128
Median402,000
Standard Deviation1,426,874
Sample Variance2T
Range4.2M
R-Value0.64
Mean Square Error1.3T
R-Squared0.42
Significance0.01
Slope205,697
Total Sum of Squares28.5T

Edgewise Non Operating Income Net Other History

20242.4 M
20234.6 M
2022M

About Edgewise Therapeutics Financial Statements

Edgewise Therapeutics investors use historical fundamental indicators, such as Edgewise Therapeutics' Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Operating Income Net Other4.6 M2.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.